Introduction: The origin, isolation, and characterization of (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E,
3Z)-3-fluoro-4-phenoxybuta-1, 3-dienyl)-3, 5-dihydroxycyclopentyl) hept-5-enoate, an impurity found in the
preparation of an anti-glaucoma agent-Tafluprost has been described in this study.
Materials and Methods: Further, an enantiospecific synthesis of (Z)-isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E, 3Z)-
3-fluoro-4-phenoxybuta-1, 3-dienyl)-3, 5-dihydroxycyclopentyl) hept-5-enoate has been revealed using deoxofluorination
as a key transformation of the strategy.
Results and Discussions: Moreover, the impurity showing anti-glaucoma properties in docking studies with respect
to bimatoprost has been described.
Conclusion: The extention of our work towards docking studies and the present impurity molecule showed almost
the same biological activity with respect to Tafluprost.